dorzagliatin – INDONESIA FOLK

ACN Newswire

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

13/05/2022

SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces … Baca lebih lajut

ACN Newswire

Hua Medicine Announces 2021 Annual Results

17/03/2022

SHANGHAI, CHINA, Mar 17, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries … Baca lebih lajut

ACN Newswire

Hua Medicine Announces 2020 Interim Results

19/08/2021

SHANGHAI, CHINA, Aug 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for … Baca lebih lajut

ACN Newswire

Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine’s Dorzagliatin Readying for NDA Submission

19/03/2021

SHANGHAI, CHINA, Mar 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries … Baca lebih lajut